Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5

Tseng, Hung Fu; Ackerson, Bradley K.; Bruxvoort, Katia J.; Sy, Lina S.; Tubert, Julia E.; Lee, Gina S.; Ku, Jennifer H.; Florea, Ana; Luo, Yi; Qiu, Sijia; Choi, Soon Kyu; Takhar, Harpreet S.; Aragones, Michael; Paila, Yamuna D.; Chavers, Scott; Talarico, Carla A.; Qian, Lei

doi:10.1038/s41467-023-35815-7

Cited by 105SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesCOVID-19 Clinical Research Studies

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5

Open access

Tseng, Hung Fu, Ackerson, Bradley K., Bruxvoort, Katia J., Sy, Lina S., Tubert, Julia E., Lee, Gina S., Ku, Jennifer H., Florea, Ana +9 more·2023·Nature Communications

DOI 10.1038/s41467-023-35815-7PMC PMC9836332

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Studies have reported reduced natural SARS-CoV-2 infection- and vaccine-induced neutralization against omicron BA.4/BA.5 compared with earlier omicron subvariants. This test-negative case-control study evaluates mRNA-1273 vaccine effectiveness (VE) against infection and hospitalization with omicron subvariants. The study includes 30,809 SARS-CoV-2 positive and 92,427 SARS-CoV-2 negative individuals aged ≥18 years tested during 1/1/2022-6/30/2022. While 3-dose VE against BA.1 infection is high and wanes slowly, VE against BA.2, BA.2.12.1, BA.4, and BA.5 infection is initially moderate to high (61.0%-90.6% 14-30 days post third dose) and wanes rapidly. The 4-dose VE against infection with BA.2, BA.2.12.1, and BA.4 ranges between 64.3%-75.7%, and is low (30.8%) against BA.5 14-30 days post fourth dose, disappearing beyond 90 days for all subvariants. The 3-dose VE against hospitalization for BA.1, BA.2, and BA.4/BA.5 is 97.5%, 82.0%, and 72.4%, respectively; 4-dose VE against hospitalization for BA.4/BA.5 is 88.5%. Evaluation of the updated bivalent booster is warranted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41467-023-35815-7

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Of three studies assessing VE against infection/symptomatic disease during both BA.2 and BA.4/BA.5 periods, all showed similar VE estimates or estimates with overlapping 95 % confidence intervals against both subvariants.
“Of three studies assessing VE against infection/symptomatic disease during both BA.2 and BA.4/BA.5 periods, all showed similar VE estimates or estimates with overlapping 95 % confidence intervals against both subvariants [25,26,31-33].”
From Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization (2023) · cites this paper as [33]
Eight studies assessed VE of primary series or first booster dose vaccination separately for at least two different Omicron subvariants (six assessed VE of both primary series and booster dose vaccination and two assessed VE of a booster dose only).
“Eight studies assessed VE of primary series or first booster dose vaccination separately for at least two different Omicron subvariants (six assessed VE of both primary series and booster dose vaccination and two assessed VE of a booster dose only, Tables 1 and 2) [21,24-26,28-33].”
From Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization (2023) · cites this paper as [33]
Among 4 studies that compared VE against outcomes of SARS-CoV-2 infection and/or symptomatic COVID-19 disease between BA.1 and BA.2, all showed lower VE against BA.2.
“Among 4 studies that compared VE against outcomes of SARS-CoV-2 infection and/or symptomatic COVID-19 disease between BA.1 and BA.2, all showed lower VE against BA.2 [26,29,31,33].”
From Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization (2023) · cites this paper as [33]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries
Quan, H., Li, B., Couris, C. M., Fushimi, K., Graham, P. J., Hider, P., Januel, J., & Sundararajan, V. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwq433 · Cited by 5,858 · see citing works
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742 · see citing works
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420 · see citing works
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
Viana, R. P. E. S., Moyo, S. M., Amoako, D. G., Tegally, H., Scheepers, C., Althaus, C. L., Anyaneji, U. J., Bester, P. A., Boni, M. F., Chand, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04411-y · Cited by 1,653 · see citing works
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., et al. (2022) · Nature · doi:10.1038/s41586-022-04980-y · Cited by 1,288 · see citing works
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Garcia-Beltran, W. F., St. Denis, K. J., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.033 · Cited by 1,045 · see citing works
Sociodemographic Characteristics of Members of a Large, Integrated Health Care System: Comparison with US Census Bureau Data
Koebnick, C., Langer-Gould, A. M., Gould, M. K., Chao, C. R., Iyer, R. L., Smith, N., Chen, W., & Jacobsen, S. J. (2012) · The Permanente Journal · doi:10.7812/tpp/12-031 · Cited by 789 · see citing works
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
Wang, Q., Guo, Y., Iketani, S., Nair, M. S., Li, Z., Mohri, H., Wang, M., Yu, J., Bowen, A. D., Chang, J. Y., et al. (2022) · Nature · doi:10.1038/s41586-022-05053-w · Cited by 768 · see citing works
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa
Tegally, H., Moir, M., Everatt, J., Giovanetti, M., Scheepers, C., Wilkinson, E., Subramoney, K., Makatini, Z., Moyo, S., Amoako, D. G., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01911-2 · Cited by 707 · see citing works
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Tuekprakhon, A., Nutalai, R., Dijokaite-Guraliuc, A., Zhou, D., Ginn, H. M., Selvaraj, M., Liu, C., Mentzer, A. J., Supasa, P., Duyvesteyn, H. M. E., et al. (2022) · Cell · doi:10.1016/j.cell.2022.06.005 · Cited by 677 · see citing works
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study
Lauring, A. S., Tenforde, M. W., Chappell, J. D., Gaglani, M., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Talbot, H. K., Casey, J. D., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069761 · Cited by 656 · see citing works
Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index
Kim, D. H., Schneeweiß, S., Glynn, R. J., Lipsitz, L. A., Rockwood, K. J., & Avorn, J. (2017) · The Journals of Gerontology Series A · doi:10.1093/gerona/glx229 · Cited by 628 · see citing works
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
Collie, S., Champion, J., Moultrie, H., Bekker, L.-G., & Gray, G. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119270 · Cited by 600 · see citing works
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
Altarawneh, H. N., Chemaitelly, H., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Coyle, P., Al-Kanaani, Z., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203965 · Cited by 551 · see citing works
Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants
Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., et al. (2022) · doi:10.1101/2022.01.07.22268919 · Cited by 541 · see citing works
Self-citation
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
Hachmann, N. P., Miller, J. J., Collier, A.-R. Y., Ventura, J. D., Yu, J., Rowe, M., Bondzie, E. A., Powers, O. C., Surve, N., Hall, K., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2206576 · Cited by 530 · see citing works
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O’Dell, S., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119912 · Cited by 442 · see citing works
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Ferdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7107e2 · Cited by 435 · see citing works
Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
Regev‐Yochay, G., Gonen, T., Gilboa, M., Mandelboim, M., Indenbaum, V., Amit, S., Meltzer, L., Asraf, K., Cohen, C., Fluss, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2202542 · Cited by 403 · see citing works
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Tang, P., Hasan, M. R., Coyle, P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200797 · Cited by 380 · see citing works
Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike
Yamasoba, D., Kimura, I., Nasser, H., Morioka, Y., Nao, N., Ito, J., Uriu, K., Tsuda, M., Zahradník, J., Shirakawa, K., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.035 · Cited by 366 · see citing works
Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022
Clarke, K. E. N., Jones, J. M., Deng, Y., Nycz, E., Lee, A., Iachan, R., Gundlapalli, A. V., Hall, A. J., & MacNeil, A. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7117e3 · Cited by 297 · see citing works
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Magen, O., Waxman, J. G., Makov-Assif, M., Vered, R., Dicker, D., Hernán, M. A., Lipsitch, M., Reis, B. Y., Balicer, R. D., & Dagan, N. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201688 · Cited by 279 · see citing works
Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
Bruxvoort, K. J., Sy, L. S., Qian, L., Ackerson, B. K., Luo, Y., Lee, G. S., Tian, Y., Florea, A., Aragones, M., Tubert, J. E., et al. (2021) · BMJ · doi:10.1136/bmj-2021-068848 · Cited by 230 · see citing works
Self-citation
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30895-3 · Cited by 228 · see citing works
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
Khan, K., Karim, F., Ganga, Y., Bernstein, M. P., Jule, Z., Reedoy, K., Cele, S., Lustig, G., Amoako, D. G., Wolter, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32396-9 · Cited by 221 · see citing works
Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study
Stowe, J., Andrews, N., Kirsebom, F., Ramsay, M., & Bernal, J. L. (2022) · Nature Communications · doi:10.1038/s41467-022-33378-7 · Cited by 166 · see citing works
Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
Qu, P., Faraone, J. N., Evans, J. P., Zou, X., Zheng, Y.-M., Carlin, C., Bednash, J. S., Lozanski, G., Mallampalli, R. K., Saif, L. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2206725 · Cited by 161 · see citing works
BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00101-1 · Cited by 149 · see citing works
Self-citation
Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study
(2022) · doi:10.1136/bmj-2022-071502 · Cited by 144 · see citing works
Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
Altarawneh, H. N., Chemaitelly, H. S., Ayoub, H. H., Hasan, M. R., Coyle, P. V., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Kanaani, Z. A., Al‐Kuwari, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2209306 · Cited by 144 · see citing works
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022
Link-Gelles, R., Levy, M. E., Gaglani, M., Irving, S. A., Stockwell, M., Dascomb, K., DeSilva, M. B., Reese, S. E., Liao, I.-C., Ong, T. C., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7129e1 · Cited by 126 · see citing works
Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study
Gazit, S., Saciuk, Y., Perez, G., Peretz, A., Pitzer, V. E., & Patalon, T. (2022) · BMJ · doi:10.1136/bmj-2022-071113 · Cited by 87 · see citing works
Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization
Feikin, D. R., Abu-Raddad, L. J., Andrews, N., Davies, M.-A., Higdon, M. M., Orenstein, W. A., & Patel, M. K. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.069 · Cited by 83 · see citing works
Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
Qu, P., Faraone, J. N., Evans, J. P., Zheng, Y.-M., Yu, L., Ma, Q., Carlin, C., Lozanski, G., Saif, L. J., Oltz, E. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2210546 · Cited by 82 · see citing works
Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants
Malato, J., Ribeiro, R. M., Leite, P. P., Casaca, P., Fernandes, E., Antunes, C., Fonseca, V. R., Gomes, M. C., & Graca, L. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2209479 · Cited by 81 · see citing works
Molecular epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022
Fonager, J., Bennedbæk, M., Bager, P., Wohlfahrt, J., Ellegaard, K. M., Ingham, A. C., Edslev, S. M., Stegger, M., Sieber, R. N., Lassauniere, R., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.10.2200181 · Cited by 78 · see citing works
BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Frankland, T. B., Ackerson, B. K., Takhar, H., Ogun, O. A., Simmons, S., Zamparo, J. M., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00692-2 · Cited by 66 · see citing works
Self-citation
Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination
Maringer, Y., Nelde, A., Schroeder, S. M., Schuhmacher, J., Hörber, S., Peter, A., Karbach, J., Jäger, E., & Walz, J. S. (2022) · Science Immunology · doi:10.1126/sciimmunol.add3899 · Cited by 61 · see citing works
The COVID-19 hospitalization metric in the pre- and postvaccination eras as a measure of pandemic severity: A retrospective, nationwide cohort study
Fillmore, N. R., La, J., Zheng, C., Doron, S., Do, N., Monach, P. A., & Branch‐Elliman, W. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.13 · Cited by 45 · see citing works
Long-term Protection Associated With COVID-19 Vaccination and Prior Infection
Tenforde, M. W., Link‐Gelles, R., & Patel, M. M. (2022) · JAMA · doi:10.1001/jama.2022.14660 · Cited by 26 · see citing works
Risk of Reinfection, Vaccine Protection, and Severity of Infection with the BA.5 Omicron Subvariant: A Danish Nation-Wide Population-Based StudyPreprint
Hansen, C. H., Friis, N. U., Bager, P., Stegger, M., Fonager, J., Fomsgaard, A., Gram, M. A., Christiansen, L. E., Ethelberg, S., Legarth, R. A., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4165630 · Cited by 21 · see citing works
Protection of SARS-CoV-2 natural infection against reinfection with the BA.4 or BA.5 Omicron subvariants
Altarawneh, H., Chemaitelly, H., Ayoub, H., Hasan, M. R., Coyle, P., Yassine, H., Khatib, H. A., Benslimane, F., Al-Kanaani, Z., Al-Kuwari, E., et al. (2022) · medRxiv · doi:10.1101/2022.07.11.22277448 · Cited by 20 · see citing works
Letter to the editor: Epidemiology of the SARS-CoV-2 variant Omicron BA.2 – vigilance needed
Huang, J., & Zeng, G. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.13.2200254 · Cited by 14 · see citing works
juliatubert/P901-Variant-VE-Manuscript---Nature-Comms: Analysis program posted
Juliatubert (2022) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.7387987 · Cited by 1 · see citing works

Flagged first, then by citations

Research works printed but not linked: 3

[5]The World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Vol. 2022 (2022).
[30]Link-Gelles R Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated — VISION Network, 10 States, december 2021–June 2022 MMWR Morbidity Mortal. Wkly. Rep. 2022 71 931 939 10.15585/mmwr.mm7129e1 PMC9310634 35862287 · DOI · Paper page
[39]Stowe J Andrews N Kirsebom F Ramsay M Bernal JL Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study Nat. Commun. 2022 13 5736 10.1038/s41467-022-33378-7 36180428 PMC9523190 · DOI · Paper page

Sorted by citations

Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study
Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00058-0 · Cited by 110 · see citing works
COVID-19 Mortality and Progress Toward Vaccinating Older Adults — World Health Organization, Worldwide, 2020–2022
Wong, M. K., Brooks, D., Ikejezie, J., Gacic-Dobo, M., Dumolard, L. B., Nedelec, Y., Steulet, C., Kassamali, Z. A., Açma, A., Ajong, B. N., et al. (2023) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7205a1 · Cited by 102 · see citing works
Wastewater-based epidemiology predicts COVID-19-induced weekly new hospital admissions in over 150 USA counties
Li, X., Liu, H., Gao, L., Sherchan, S. P., Zhou, T., Khan, S. J., van Loosdrecht, M. C. M., & Wang, Q. (2023) · Nature Communications · doi:10.1038/s41467-023-40305-x · Cited by 82 · see citing works
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study
Andersson, N. W., Thiesson, E. M., Baum, U., Pihlström, N., Starrfelt, J., Faksová, K., Poukka, E., Meijerink, H., Ljung, R., & Hviid, A. P. (2023) · BMJ · doi:10.1136/bmj-2022-075286 · Cited by 92 · see citing works
Tracking the COVID-19 vaccines: The global landscape
Yadav, T., Kumar, S., Mishra, G., & Saxena, S. K. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2191577 · Cited by 76 · see citing works
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
Chalkias, S., Whatley, J. L., Eder, F. S., Essink, B. J., Khetan, S. K., Bradley, P., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02517-y · Cited by 73 · see citing works
mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States
Tseng, H. F., Ackerson, B. K., Sy, L. S., Tubert, J. E., Luo, Y., Qiu, S., Lee, G. S., Bruxvoort, K. J., Ku, J. H., Florea, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41537-7 · Cited by 67 · see citing works
Self-citation
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates
Gagné, M., Flynn, B. J., Andrew, S. F., Marquez, J., Flebbe, D. R., Mychalowych, A., Lamb, E., Davis-Gardner, M. E., Burnett, M. R., Serebryannyy, L., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01951-5 · Cited by 74 · see citing works
Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · Nature · doi:10.1038/s41586-024-08511-9 · Cited by 59 · see citing works
Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022
Surie, D., Bonnell, L., Adams, K., Gaglani, M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7142a3 · Cited by 59 · see citing works
Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
(2023) · doi:10.1038/s41467-023-36566-1 · Cited by 59 · see citing works
Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine
Feng, Y., Yuan, M., Powers, J. M., Hu, M., Munt, J. E., Arunachalam, P. S., Leist, S. R., Bellusci, L., Kim, J., Sprouse, K. R., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg7404 · Cited by 58 · see citing works
Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines
Chalkias, S., McGhee, N., Whatley, J. L., Essink, B. J., Brosz, A. B., Tomassini, J. E., Girard, B., Edwards, D. K., Wu, K., Nasir, A., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae067 · Cited by 56 · see citing works
Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization
Feikin, D. R., Higdon, M. M., Andrews, N., Collie, S., Deloria Knoll, M., Kwong, J. C., Link-Gelles, R., Pilishvili, T., & Patel, M. K. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.020 · Cited by 36 · see citing works
“Hospitalization for acute respiratory infection <3 m 80 (74, 84) 74 (47, 87) 3–5 m 72 (13, 91) 3 m 76 (69, 82) 70 (53, 81) 6 m 38 (-31, 71) Tseng et al (USA, any mRNA) [33] Infection 18 14–30 d 85.”
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases
Baden, L. R., Sahly, H. M. E., Essink, B. J., Follmann, D. A., Hachigian, G., Strout, C. B., Overcash, J. S., Doblecki‐Lewis, S., Whitaker, J. A., Anderson, E. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50376-z · Cited by 37 · see citing works
Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome
Lewnard, J. A., Hong, V. X., Kim, J. S., Shaw, S. F., Lewin, B. J., Takhar, H. S., & Tartof, S. Y. (2023) · Nature Communications · doi:10.1038/s41467-023-37051-5 · Cited by 33 · see citing works
Self-citation
Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies
Song, S., Madewell, Z. J., Liu, M., Longini, I. M., & Yang, Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1195908 · Cited by 34 · see citing works
Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study
Qassim, S. H., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102102 · Cited by 32 · see citing works
COVID-19 annual update: a narrative review
Biancolella, M., Colona, V., Luzzatto, L., Watt, J., Mattiuz, G., Conticello, S., Kaminski, N., Mehrian-Shai, R., Ko, A., Gonsalves, G., et al. (2023) · Human Genomics · doi:10.1186/s40246-023-00515-2 · Cited by 30 · see citing works
Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the Nordic countriesPreprint
Andersson, N. W., Thiesson, E. M., Baum, U., Pihlström, N., Starrfelt, J., Faksová, K., Poukka, E., Meijerink, H., Ljung, R., & Hviid, A. P. (2023) · medRxiv · doi:10.1101/2023.01.19.23284764 · Cited by 31 · see citing works
Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination
Zhao, X., Qiu, T., Huang, X., Mao, Q., Wang, Y., Qiao, R., Li, J., Mao, T., Wang, Y., Cun, Y., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00648-1 · Cited by 30 · see citing works
Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages
Ackerson, B. K., Bruxvoort, K. J., Qian, L., Sy, L. S., Qiu, S., Tubert, J. E., Lee, G. S., Ku, J. H., Florea, A., Luo, Y., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2335052 · Cited by 26 · see citing works
Self-citation
Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: a national cohort study in Qatar
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · eLife · doi:10.7554/elife.103690 · Cited by 26 · see citing works
Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination
Pérez, C. M., Aguilar, R., Jiménez, A., Salmerón, G., Canyelles, M., Rubio, R., Vidal, M., Cuamba, I., Barrios, D., Díaz, N., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03304-3 · Cited by 25 · see citing works
SARS-CoV-2 before and after Omicron: two different viruses and two different diseases?
Gili, R., & Burioni, R. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04095-6 · Cited by 25 · see citing works
The Coming of Age of Nucleic Acid Vaccines during COVID-19
Rando, H. M., Lordan, R., Kolla, L., Sell, E., Lee, A. J., Wellhausen, N., Naik, A. S., Kamil, J. P., Gitter, A., Greene, C. S., et al. (2023) · mSystems · doi:10.1128/msystems.00928-22 · Cited by 29 · see citing works
Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada
Carazo, S., Skowronski, D. M., Brisson, M., Sauvageau, C., Brousseau, N., Fafard, J., Gilca, R., Talbot, D. C., Ouakki, M., Febriani, Y., et al. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00099-5 · Cited by 24 · see citing works
Metal‐Coordinated, Dual‐Crosslinked PIM Polymer Membranes for Upgraded CO 2 Separation: Aging and Plasticization Resistance
Hossain, I., Kim, K. I., Husna, A., Kang, J. H., Kim, T., & Park, H. B. (2024) · Small · doi:10.1002/smll.202407973 · Cited by 22 · see citing works
Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant
Chemaitelly, H. S., Coyle, P. V., Kacem, M. A. B. H., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2024) · Journal of Travel Medicine · doi:10.1093/jtm/taae053 · Cited by 21 · see citing works
Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study
Huiberts, A. J., de Gier, B., Hoeve, C. E., de Melker, H. E., Hahné, S., den Hartog, G., Grobbee, D. E., van de Wijgert, J. H. H. M., van den Hof, S., & Knol, M. J. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.04.401 · Cited by 21 · see citing works
Protection Conferred by COVID-19 Vaccination, Prior SARS-CoV-2 Infection, or Hybrid Immunity Against Omicron-Associated Severe Outcomes Among Community-Dwelling Adults
Lee, N. L. S., Nguyen, L., Austin, P. C., Brown, K. A., Grewal, R., Buchan, S. A., Nasreen, S., Gubbay, J. B., Schwartz, K. L., Tadrous, M., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad716 · Cited by 20 · see citing works
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
Bennett, C., Woo, W., Bloch, M., Cheung, K., Griffin, P. M., Mohan, R., Deshmukh, S., Arya, M., Cumming, O., Neville, A. M., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00077-x · Cited by 19 · see citing works
Self-citation
SARS-CoV-2: The Interplay Between Evolution and Host Immunity
Case, J. B., Jain, S., Suthar, M. S., & Diamond, M. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-083122-043054 · Cited by 22 · see citing works
Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai
Wu, Q., Wang, H., Cai, J., Ai, J., Li, Y., Zhang, H., Wang, S., Sun, F., Wu, Y., Zhou, J., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2169197 · Cited by 16 · see citing works
Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient
Sukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Yassine, H. M., Thani, A. A. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.026 · Cited by 17 · see citing works
Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination
Walmsley, S. L., Nabipoor, M., Lovblom, L. E., Ravindran, R., Colwill, K., McGeer, A., Dayam, R. M., Manase, D., Gingras, A., & on behalf of the STOPCoV Team (2023) · Vaccines · doi:10.3390/vaccines12010036 · Cited by 14 · see citing works
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial
Bennett, C., Rivers, E. J., Woo, W., Bloch, M., Cheung, K., Griffin, P. M., Mohan, R., Deshmukh, S., Arya, M., Cumming, O., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad508 · Cited by 13 · see citing works
An ancestral SARS-CoV-2 vaccine induces anti-Omicron variants antibodies by hypermutation
Park, S., Choi, J., Lee, Y., Noh, J., Kim, N., Lee, J., Cho, G., Kim, S., Yoo, D. K., Kang, C. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47743-1 · Cited by 13 · see citing works
Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis
Yamamoto, S., Matsuda, K., Maeda, K., Horii, K., Okudera, K., Oshiro, Y., Inamura, N., Nemoto, T., Takeuchi, J. S., Li, Y., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad317 · Cited by 13 · see citing works
Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission
Benlarbi, M., Ding, S., Bélanger, É., Tauzin, A., Poujol, R., Medjahed, H., Ferri, O. E., Bo, Y., Bourassa, C., Hussin, J., et al. (2024) · mBio · doi:10.1128/mbio.00907-24 · Cited by 12 · see citing works
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases
Brandi, R., Paganelli, A., D’Amelio, R., Giuliani, P., Lista, F. R., Salemi, S., & Paganelli, R. (2024) · Vaccines · doi:10.3390/vaccines12121418 · Cited by 12 · see citing works
Increased vaccine sensitivity of an emerging SARS-CoV-2 variant
Lewnard, J. A., Hong, V. X., Kim, J. S., Shaw, S. F., Lewin, B. J., Takhar, H. S., Lipsitch, M., & Tartof, S. Y. (2023) · Nature Communications · doi:10.1038/s41467-023-39567-2 · Cited by 11 · see citing works
Self-citation
Early humoral and cellular responses after bivalent SARS‐CoV‐2 mRNA‐1273.214 vaccination in long‐term care and retirement home residents in Ontario, Canada: An observational cohort study
Breznik, J. A., Rahim, A., Bhakta, H., Clare, R., Zhang, A., Ang, J. C., Stacey, H. D., Liu, L., Kennedy, A. E., Bilaver, L., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29170 · Cited by 11 · see citing works
All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data
Alessandria, M., Malatesta, G., Palmo, G. D., Cosentino, M., & Donzelli, A. (2024) · F1000Research · doi:10.12688/f1000research.154058.1 · Cited by 11 · see citing works
Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study
Ku, J. H., Sy, L. S., Qian, L., Ackerson, B. K., Luo, Y., Tubert, J. E., Lee, G. S., Florea, A., Bruxvoort, K. J., Xie, F., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.016 · Cited by 11 · see citing works
Self-citation
Understanding the time-driven shifts of vaccine effectiveness against any and severe COVID-19 before and after the surge of Omicron variants within 2.5 years of vaccination: A meta-regression
Petráš, M., Janovská, D., Lomozová, D., Franklová, M., Dlouhý, P., Rosina, J., & Lesná, I. K. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.106986 · Cited by 10 · see citing works
T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets
Nowill, A. E., Caruso, M., & de Campos-Lima, P. O. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133225 · Cited by 10 · see citing works
Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Preprint
Chalkias, S., Whatley, J. L., Eder, F. S., Essink, B. J., Khetan, S. K., Bradley, P., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., et al. (2022) · medRxiv · doi:10.1101/2022.12.11.22283166 · Cited by 10 · see citing works
A Direct Infection Risk Model for CFD Predictions and Its Application to SARS‐CoV‐2 Aircraft Cabin Transmission
Webner, F., Shishkin, A., Schmeling, D., & Wagner, C. D. (2024) · Indoor Air · doi:10.1155/2024/9927275 · Cited by 10 · see citing works
Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination
Walmsley, S. L., Nabipoor, M., Qi, F., Lovblom, L. E., Ravindran, R., Colwill, K., Dayam, R. M., Tursun, T. R., Silva, A., Gingras, A., et al. (2024) · Vaccines · doi:10.3390/vaccines12060564 · Cited by 10 · see citing works
Humoral and cellular immunity against diverse SARS-CoV-2 variants
Chen, C., Wang, X., & Zhang, Z. (2023) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2023.10.003 · Cited by 9 · see citing works
Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial
Figueroa, A. L., Ali, K., Berman, G., Zhou, H., Deng, W., Xu, W., Lussier, S. J., Girard, B., Dutko, F. J., Slobod, K., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102720 · Cited by 8 · see citing works
Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman PrimatesPreprint
Gagné, M., Flynn, B. J., Andrew, S. F., Flebbe, D. R., Mychalowych, A., Lamb, E., Davis-Gardner, M. E., Burnett, M. R., Serebryannyy, L., Lin, B. C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.06.565765 · Cited by 9 · see citing works
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study
Essink, B. J., Shapiro, C., Isidro, M. G. D., Bradley, P., Pragalos, A., Bloch, M., Santiaguel, J., Frias, M. V., Miyakis, S., Alves de Mesquita, M., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2408863 · Cited by 8 · see citing works
The immunological impact of revaccination in a hybrid-immune world
Bausch-Jurken, M. T., & Alter, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1588259 · Cited by 8 · see citing works
Association between vaccination status and severe health consequences among community-dwelling COVID-19 patients during Omicron BA.1/BA.2 and BA.5-predominant periods in Japan
Tomioka, K., Uno, K., & Yamada, M. (2023) · Environmental Health and Preventive Medicine · doi:10.1265/ehpm.23-00061 · Cited by 8 · see citing works
A Comprehensive Review of mRNA-based Vaccines for COVID-19, A New Era in Pharmaceuticals: Unspecified and Unknown Aspects, Effects and Challenges
Vosoughi, P., Naghib, S. M., Rahmanian, M., & Mozafari, M. R. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266325847241121034100 · Cited by 7 · see citing works
Previous SARS-CoV-2 infections and their impact on the protection from reinfection during the Omicron BA.5 wave – a nested case-control study among vaccinated adults in Sweden
Kahn, F., Bonander, C., Moghaddassi, M., Christiansen, C. B., Bennet, L., Malmqvist, U. P., Inghammar, M., & Björk, J. (2024) · IJID Regions · doi:10.1016/j.ijregi.2024.02.004 · Cited by 6 · see citing works
Effectiveness of mRNA-1273 bivalent (Original and Omicron BA.4/BA.5) COVID-19 vaccine in preventing hospitalizations for COVID-19, medically attended SARS-CoV-2 infections, and hospital death in the United StatesPreprint
Tseng, H. F., Ackerson, B. K., Sy, L. S., Tubert, J. E., Luo, Y., Qiu, S., Lee, G. S., Bruxvoort, K. J., Ku, J. H., Florea, A., et al. (2023) · medRxiv · doi:10.1101/2023.05.25.23290456 · Cited by 7 · see citing works
Self-citation
Impact of unequal testing on vaccine effectiveness estimates across two study designs: a simulation study
Bodner, K., Wang, L., Kustra, R., Kwong, J. C., Sander, B., Sbihi, H., Irvine, M. A., & Mishra, S. (2025) · Nature Communications · doi:10.1038/s41467-025-59768-1 · Cited by 5 · see citing works
All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data
Alessandria, M., Malatesta, G., Palmo, G. D., Cosentino, M., & Donzelli, A. (2025) · F1000Research · doi:10.12688/f1000research.154058.2 · Cited by 5 · see citing works
COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2
Chen, W., Hu, S.-Y., Shen, C., Chuang, H., Ker, C.-R., Shen, C.-J., & Cheng, C. (2023) · Vaccines · doi:10.3390/vaccines11091425 · Cited by 5 · see citing works
How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021 to September 2022
Althaus, T., Overton, C. E., Devaux, I., House, T., Lapouze, A., Troel, A., Vanzo, B., Laroche, M., Bordero, A., Jorgensen, P., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03444-6 · Cited by 5 · see citing works
Effect of Age, Sex, and COVID-19 Vaccination History on All-Cause Mortality: Unexpected Outcomes in a Complex Biological and Social SystemPreprint
Jones, R., & Ponomarenko, A. (2023) · Preprints.org · doi:10.20944/preprints202304.0248.v1 · Cited by 4 · see citing works
Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
Figueroa, A. L., Ali, K., Berman, G., Xu, W., Deng, W., Girard, B., Yeakey, A. M., Slobod, K., Miller, J. M., Das, R., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2436714 · Cited by 4 · see citing works
Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection
Pérez, C. M., Ramírez‐Morros, A., Jiménez, A., Vidal, M., Pradenas, E., Barrios, D., Canyelles, M., Rubio, R., Cuamba, I., Izquierdo, L., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00943-2 · Cited by 4 · see citing works
Antibody response to inactivated COVID ‐19 vaccine in patients with type 2 diabetes mellitus after the booster immunization
Li, H., Wang, Y., Li, X., Wang, S., Feng, X., Xiao, X., & Li, Y. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13448 · Cited by 4 · see citing works
Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta infectionsPreprint
Altarawneh, H. N., Chemaitelly, H. S., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Thani, A. A. A., Coyle, P. V., Kanaani, Z. A., et al. (2023) · medRxiv · doi:10.1101/2023.04.21.23288917 · Cited by 4 · see citing works
Effectiveness and durability of a fourth dose of ancestral-strain mRNA vaccines against SARS-CoV-2 infection: a nationwide matched cohort study in Qatar
Sukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-19168-3 · Cited by 3 · see citing works
Correlation of SARS-CoV-2 Neutralization with Antibody Levels in Vaccinated Individuals
Chowdhury, S. H., Riley, S., Mikolajczyk, R., Smith, L. N., Suresh, L., & Jacobs, A. (2023) · Viruses · doi:10.3390/v15030793 · Cited by 3 · see citing works
Efficacy of COVID-19 Vaccines against the Omicron Variant of SARS-CoV-2: A Review
Rajsri, K. S., Singh, M., & Rao, M. (2023) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2023.00023 · Cited by 2 · see citing works
COVID-19 boosters versus primary series: update to a living review
Wu, N., Joyal‐Desmarais, K., Vieira, A. M., Sanuade, C. T., Jagwani, M., Paquet, L., Ribeiro, P. A. B., Stojanovic, J., Yip, D., & Bacon, S. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00265-5 · Cited by 3 · see citing works
Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants
Ong, C., Tang, K., Cheung, P.-H. H., Zhang, H., Tang, T.-T., Xue, Y., Wang, J., To, K. K., Yuan, S.-F., Ye, Z., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00776-x · Cited by 3 · see citing works
Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study
Amstutz, A., Chammartin, F., Audigé, A., Eichenberger, A. L., Braun, D. L., Amico, P., Stoeckle, M. P., Hasse, B. K., Papadimitriou‐Olivgeris, M., Manuel, O., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae291 · Cited by 3 · see citing works
Broad‐spectrum coronavirus neutralization induced by hetero RBD‐Fc protein vaccine
Zhao, C., Cai, G., Jiang, S., Wang, X., Li, C., Liu, X., Qiao, R., Zhao, X., Cui, Y., Chen, Y., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29917 · Cited by 3 · see citing works
Breakthrough COVID-19 Infections after Booster SARS-CoV-2 Vaccination in a Greek Cohort of People Living with HIV during the Delta and Omicron Waves
Protopapas, K., Thomas, Κ., Moschopoulos, C. D., Oktapoda, E., Marousi, E., Marselou, E., Stamoulis, N., Filis, C., Kazakou, P., Oikonomopoulou, C., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12071614 · Cited by 2 · see citing works
Comparative effectiveness of one versus two doses of COVID-19 vaccines in Qatar: Evidence of converging protection over time
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127556 · Cited by 2 · see citing works
Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11410-7 · Cited by 2 · see citing works
Duration of vaccine protection against breakthrough infections during five COVID-19 waves among healthcare workers primarily vaccinated with CoronaVac
Luna-Muschi, A., Borges, I. C., Barboza, A. D. S., de Faria, E., Côrtes, M. F., Santos, R. B., Silva, B. C., da Silva, C. A. M., Rocha, E., de Souza, V. R., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.07.015 · Cited by 2 · see citing works
Longitudinal humoral immunity against SARS-CoV-2 Spike following infection in individuals from Cameroon
Benlarbi, M., Kenfack, D.-D., Dionne, K., Côté-Chenette, M., Beaudoin-Bussières, G., Bélanger, É., Ding, S., Hamadama, O. G., Ngoume, Y. F., Tauzin, A., et al. (2025) · Virology · doi:10.1016/j.virol.2025.110467 · Cited by 2 · see citing works
Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial
Figueroa, A. L., Torres, D., Reyes-Acuna, C., Matherne, P. G., Yeakey, A. M., Deng, W., Xu, W., Sigal, Y., Chambers, G., Olsen, M., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00501-2 · Cited by 2 · see citing works
Prior infection- and/or vaccine-induced protection against Omicron BA.1, BA.2 and BA.4/BA.5-related hospitalisations in older adults: a test-negative case-control study in Quebec, CanadaPreprint
Carazo, S., Skowronski, D. M., Brisson, M., Sauvageau, C., Brousseau, N., Fafard, J., Gilca, R., Talbot, D. C., Ouakki, M., Febriani, Y., et al. (2022) · medRxiv · doi:10.1101/2022.12.21.22283740 · Cited by 2 · see citing works
The Crucial Role of COVID-19 Vaccination in Preventing Severe Illness and Death: Evidence From a Korean Perspective
Jung, J. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e100 · Cited by 2 · see citing works
Effectiveness of interventions to reduce COVID-19 transmission in schools
Pasco, R. F., Fox, S. J., Lachmann, M., & Ancel, L. W. (2024) · Epidemics · doi:10.1016/j.epidem.2024.100762 · Cited by 1 · see citing works
Effectiveness of pre-Omicron COVID-19 mRNA vaccines against hospitalizations in infection-naïve children: a case-control study
Chang, L., Huang, C.-Y., Chiu, N., Wang, J., Chi, H., & Huang, T.-N. D. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1387086 · Cited by 1 · see citing works
Protection conferred by SARS-CoV-2 infection across a spectrum of reinfection symptoms and severities
Sukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-002718 · Cited by 1 · see citing works
Six-month follow-up of antibody response to bivalent mRNA SARS-CoV-2 vaccine booster in healthcare workers
Fedele, G., Schiavoni, I., Trentini, F., Leone, P., Olivetta, E., Fiore, S., Martino, A. D., Abrignani, S., Bandera, A., Clerici, P., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127524 · Cited by 1 · see citing works
SARS-CoV-2-specific B cell responses in non-draining lymph nodes and antibody functionalities in immunized end-stage renal disease patients
Frölke, S. C., Geers, D., Amirkhan, K. G., Pathmarajah, D. S., van der Bom‐Baylon, N. D., Idu, M. M., van Gils, M. J., Claireaux, M. A. F., Geerlings, S. E., Rispens, T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-27815-y · Cited by 1 · see citing works
Criticism of the HAS Opinion of July 21st, 2022, on Maintaining of the SARS-Cov-2 Vaccine Mandate for Healthcare Workers
Sainton, J. (2023) · Coronaviruses · doi:10.2174/2666796704666230804103419 · Cited by 1 · see citing works
Effectiveness of Bivalent mRNA Booster Vaccine Against COVID-19 in Korea
Yoon, J. G., Sohn, J. W., Choi, W. S., Wie, S., Lee, J., Lee, J. S., Jeong, H. W., Eom, J. S., Seong, H., Nham, E., et al. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2024.39.e15 · Cited by 1 · see citing works
Immunogenicity of bivalent versus monovalent mRNA booster vaccination among adult paramedics in Canada who had received three prior mRNA wild-type doses
Asamoah-Boaheng, M., Goldfarb, D. A., Kayda, I., Yap, J., Kirkham, T. L., Karim, M. E., Demers, P. A., Copp, J. M., & Grunau, B. E. (2025) · Access Microbiology · doi:10.1099/acmi.0.000791.v3 · Cited by 1 · see citing works
Worldwide Big Data Analysis Suggests COVID Vaccination Elevates Excess Mortality Of Countries Months After InitiationPreprint
Sakura, K. (2023) · doi:10.31219/osf.io/rczfu · Cited by 1 · see citing works
The nonspecific effects of COVID-19 vaccination upon non-COVID-19 all-cause mortality (NCACM) in the population of England: Effects of age, sex, COVID-19 variant, vaccination history, and time in a real-world study from Jan-21 to May-23Preprint
Jones, R., & Ponomarenko, A. (2024) · Preprints.org · doi:10.20944/preprints202401.0333.v1
Approaches for estimating COVID-19 vaccine effectiveness using observational data in administrative databases: a systematic reviewPreprint
Chow, J. Y., Goh, Z. J., Li, R., Lim, D. Z. Y., Wee, L. E., Lye, D. C., Tan, K. B., & Lim, J. T. (2025) · medRxiv · doi:10.1101/2025.09.29.25336864 · Cited by 1 · see citing works
Criticism of the HAS Opinion of 21 July 2022 Pertaining the Maintenance of SARS-Cov-2 Vaccine Mandate for Healthcare Workers in FrancePreprint
Sainton, J. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4396242
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of Highly vaccinated North Temperate Zone and North Frigid Zone CountriesPreprint
Sakura, K. (2024) · doi:10.31219/osf.io/zv6j8
The Effectiveness of COVID-19 Vaccines During the Pre-Omicron and Omicron Periods: A Retrospective Test-Negative Case–Control Study
Brambilla, R., Gili, R., Vigna‐Taglianti, F., Lenzi, J., Riccò, M., Burioni, R., Scarvaglieri, M., Rocco, R., Buttafuoco, V., Cristaudo, R. M. T. A., et al. (2024) · Vaccines · doi:10.3390/vaccines12111245
Mathematical analysis of the COVID-19 pandemic dynamics in the emergence of resistant strains of SARS-CoV-2 in a vaccinated and non-vaccinated population: a real-world scenario in most countries
de León, U. A.-P., Pérez, Á. G. C., & Avila-Vales, E. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-44-328814-2.00009-6
Additional file 1 of How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021 to September 2022
Althaus, T., Overton, C. E., Devaux, I., House, T., Lapouze, A., Troel, A., Vanzo, B., Laroche, M., Bordero, A., Jorgensen, P., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25980533
Assessing the Impact of the Healthy Vaccinee Effect on COVID-19 Vaccine Effectiveness EstimatesPreprint
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2026) · medRxiv · doi:10.64898/2026.01.02.26343330

Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants
Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., et al. (2022) · doi:10.1101/2022.01.07.22268919 · Cited by 541 · see citing works
Self-citation
Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022
Surie, D., Bonnell, L., Adams, K., Gaglani, M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7142a3 · Cited by 59 · see citing works
Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages
Ackerson, B. K., Bruxvoort, K. J., Qian, L., Sy, L. S., Qiu, S., Tubert, J. E., Lee, G. S., Ku, J. H., Florea, A., Luo, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25546628
Self-citation
Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis
Rahman, M. O., Kamigaki, T., Thandar, M. M., Haruyama, R., Yan, F., Shibamura-Fujiogi, M., Khin Maung Soe, J., Islam, M. R., Yoneoka, D., Miyahara, R., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-076892 · Cited by 29 · see citing works
Effectiveness of the Booster Doses of mRNA Vaccine Against SARS-CoV-2 Omicron Infection and its Severe Outcomes: A Systematic Review and Meta-AnalysisPreprint
Rahman, O., Kamigaki, T., Thandar, M. M., Haruyama, R., Yan, F., Shibamura‐Fujiogi, M., Soe, J. K. M., Islam, M. R., Yoneoka, D., Miyahara, R., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4445180

Authors: Tseng, H. F., Ackerson, B. K., Bruxvoort, K. J., Sy, L. S., Tubert, J. E., Lee, G. S., Ku, J. H., Florea, A., Luo, Y., Qiu, S., Choi, S. K., Takhar, H. S., Aragones, M., Paila, Y. D., Chavers, S., Talarico, C. A., & Qian, L.
Affiliations: Kaiser Permanente (US)
AstraZeneca (United States) (US)
Corresponding author: Tseng, Hung Fu
ORCID: Tseng, Hung Fu
Ackerson, Bradley K.
Bruxvoort, Katia J.
Sy, Lina S.
Tubert, Julia E.
Lee, Gina S.
Ku, Jennifer H.
Florea, Ana
Luo, Yi
Qiu, Sijia
Choi, Soon Kyu
Takhar, Harpreet S.
Talarico, Carla A.
Qian, Lei
Venue: Nature Communications
Publisher: Springer Science and Business Media LLC
Published: 2023-01-12
Volume: 14
Issue: 1
Pages: 189-189
ISSN: 2041-1723 (ISSN-L)
DOI: 10.1038/s41467-023-35815-7
PMC: PMC9836332
OpenAlex: W4315779712
Cited by: 105
References: 44
Citations by year: 2026: 5 · 2025: 18 · 2024: 33 · 2023: 46 · 2022: 3
FWCI: 20.99
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (tdm)
creativecommons.org/licenses/by/4.0 (vor)
Locations: Nature Communications (publishedVersion, cc-by)
medRxiv (acceptedVersion)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: Moderna, Inc.
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords: mRNA-1273 vaccine, SARS-CoV-2 Omicron subvariants, vaccine effectiveness, BA.1, BA.2, BA.2.12.1, BA.4, BA.5, COVID-19 infection, hospitalization, waning immunity, bivalent booster, neutralizing antibodies
MeSH terms: COVID-19, SARS-CoV-2, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Humans, Vaccination, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks